VERAXA Biotech (NASDAQ: VRXA) is refocusing its efforts on advancing its oncology pipeline and securing industrial partnerships for its technology platforms and products, according to a first-half progress report from Xlife Sciences AG. The strategic shift follows the completion of VERAXA’s business combination and the commencement of trading on the Nasdaq in June 2026. Xlife Sciences, a Swiss incubator and accelerator, said VERAXA has secured a financing base to support its next development steps and remains a key component of its portfolio strategy.
Xlife Sciences also detailed operational and scientific advancements across its portfolio during the first half of 2026, including progress at x-kidney diagnostics, saniva diagnostics, Axenoll, FUSE-AI and inflamed pharma. The portfolio now comprises 416 patents and patent applications, of which 216 are granted intellectual property rights. This robust IP position underscores the company’s commitment to bridging research and development with healthcare markets. For the second half of 2026, Xlife Sciences said it will continue to support VERAXA in establishing industry partnerships while pursuing commercialization and further development across its portfolio. The full report is available at https://ibn.fm/LwLwP.
VERAXA Biotech, founded on scientific breakthroughs at the European Molecular Biology Laboratory (EMBL), is building a premier engine for the discovery and development of next-generation antibody-based therapeutics. Its pipeline includes bispecific T cell engagers, bispecific ADCs and other innovative formats. The company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond, guided by rigorous quality-by-design principles. More information about VERAXA is available at VERAXA Biotech (NASDAQ: VRXA).
Xlife Sciences AG focuses on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, aiming to provide solutions for high unmet medical needs and a better quality of life. The company takes carefully selected projects in four areas—technological platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health—to the next stage of development and participates in their subsequent performance. For more details, visit www.xlifesciences.ch.
The news matters because VERAXA’s Nasdaq listing and renewed focus on oncology could accelerate the development of novel antibody-based therapeutics, while Xlife Sciences’ broad portfolio progress and extensive patent estate signal potential for multiple value inflection points. As VERAXA pursues industry partnerships, it may attract further investment and collaboration, impacting the competitive landscape for cancer treatments. The latest updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
